NCT05668858View on ClinicalTrials.gov

A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
DRUG

SI-B001

Administration by intravenous infusion

DRUG

SI-B003

Administration by intravenous infusion

Trial Locations (1)

200000

RECRUITING

Shanghai Oriental Hospital, Shanghai

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY